Compare USEG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | SCLX |
|---|---|---|
| Founded | 1966 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 48.5M |
| IPO Year | 1995 | N/A |
| Metric | USEG | SCLX |
|---|---|---|
| Price | $1.01 | $9.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 107.8K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,379,000.00 | N/A |
| Revenue This Year | $114,854.51 | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $4.20 |
| 52 Week High | $2.75 | $34.27 |
| Indicator | USEG | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 64.23 |
| Support Level | $0.94 | $7.73 |
| Resistance Level | $1.08 | $9.00 |
| Average True Range (ATR) | 0.05 | 0.75 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 85.80 | 79.81 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.